Evidence map›Paper›PMID 23909424›Full record

ArticleMonoclonal antibodies in immunodiagnosis and immunotherapy2013

A monoclonal antibody produced against Naked2.

Chang Cao, Shengyu Wang, Sha Lv, Zhe Li, Xianjiang Wang, Fanwei Zeng, Haipeng Zhang, Yujuan Dai, Xiaofeng Dou, Xiaoli Chen and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Monoclonal antibodies in immunodiagnosis and immunotherapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Chang CaoCancer Research Center, Medical College, Xiamen University, Xiamen, Fujian, China.
Shengyu Wang
Sha Lv
Zhe Li
Xianjiang Wang
Fanwei Zeng
Haipeng Zhang
Yujuan Dai
Xiaofeng Dou
Xiaoli Chen
Xiudong Li
Lingli Luo
Tianhui Hu
Jianghua Yan
Xiamen University · CNFirst Affiliated Hospital of Xiamen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Naked2 (NKD2) is a member of the Naked family and negatively regulates canonical Wnt signaling. NKD2 may play a role in embryo development and tumor formation by affecting Wnt signaling. In the present study, we describe the establishment of a monoclonal antibody against NKD2 (anti-NKD2 MAb) through the hybridoma method. The purified anti-NKD2 MAb measured a titer of 2.56 × 10(5) against NKD2 by indirect ELISA. Western blot analysis, immunoprecipitation, and confocal microscope showed that the anti-NKD2 MAb can specifically combine NKD2 protein in SW480 and LOVO cells. Competitive inhibition assays of Western blot and indirect ELISA showed that the anti-NKD2 MAb can be blocked with NKD2(1-217) protein. The anti-NKD2 MAb would be helpful for further studies on the structure activity relationship, protein detecting, and cell-signaling pathway of NKD2.

Indexed as

Adaptor Proteins, Signal TransducingAnimalsAntibodies, MonoclonalAntibody FormationAntibody SpecificityBlotting, WesternCalcium-Binding ProteinsCarrier ProteinsColorectal NeoplasmsEnzyme-Linked Immunosorbent AssayFemaleFlow CytometryHumansHybridomasImmunizationImmunoprecipitationAdaptor Proteins, Signal TransducingAntibodies, MonoclonalCalcium-Binding ProteinsCarrier ProteinsNKD2 protein, humanRecombinant Proteins

Identifiers

PMID23909424
PMCPMC3733319
OpenAlexW2073680872

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.